Monte Rosa Therapeutics, Inc. GLUE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $42.95M-65.3% | $123.67M-31.9% | $181.54M+2.0% | $177.99M+11.6% | $159.49M+111% | ||
| $153.38M+8.4% | $141.5M+2.2% | $138.39M+7.0% | $129.33M+2.1% | $126.73M+4.2% | ||
| $37.85M+4.0% | $36.38M+5.0% | $34.64M+2.8% | $33.7M-3.4% | $34.89M-0.8% | ||
| $191.23M+7.5% | $177.88M+2.8% | $173.03M+6.1% | $163.03M+0.9% | $161.62M+3.1% | ||
| -$148.28M-174% | -$54.21M— | —— | —— | —— | ||
| -345.2%-301pp | -43.8%— | —— | —— | —— | ||
| $15.09M+16.6% | $12.94M+9.2% | $11.85M-1.2% | $11.99M+3.7% | $11.56M+9.4% | ||
| $16.4M+13.2% | $14.49M+7.8% | $13.44M-0.2% | $13.47M+16.2% | $11.59M+5.5% | ||
| -$131.88M-232% | -$39.72M— | —— | —— | —— | ||
| -$1.93M-66.6% | -$1.16M-215% | $1.01M-76.3% | $4.26M+28.6% | $3.31M+28.8% | ||
| -$129.99M-237% | -$38.6M— | —— | —— | —— | ||
| -302.6%-271pp | -31.2%— | —— | —— | —— | ||
| -$139.94M-205% | -$45.85M— | —— | —— | —— | ||
| -325.8%-289pp | -37.1%— | —— | —— | —— | ||
| -$148.28M-174% | -$54.21M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s revenue?
- Monte Rosa Therapeutics, Inc. (GLUE) generated $43.0M in revenue over the trailing twelve months, down 73.1% year over year.
- Is Monte Rosa Therapeutics, Inc. profitable?
- Monte Rosa Therapeutics, Inc. is not currently profitable: it reported a net loss of $130.0M over the trailing twelve months, a -302.6% net margin.
- What is Monte Rosa Therapeutics, Inc.'s earnings per share?
- Monte Rosa Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.48.
- Where does Monte Rosa Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
